Clinical trial
Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's Lymphoma
NCT00081861 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00081861 |
|---|---|
| Title | Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's Lymphoma |
| Official title | A Phase II Study of Avastin Plus Rituximab for Patients With Relapsed and Chemotherapy- or Rituxan-Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | Avastin, Rituximab |
| Enrollment | 13 |
| Start date | Mar 1, 2004 |
| Primary completion | Sep 1, 2007 |
| Completion | Sep 1, 2007 |
| First posted | Apr 27, 2004 |
| Last update posted | Apr 5, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: